about
The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urineHuntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptorsNuclear LYRIC/AEG-1 interacts with PLZF and relieves PLZF-mediated repressionExpression of RAC 3, a steroid hormone receptor co-activator in prostate cancerRegulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylationStructural basis for the nuclear import of the human androgen receptorQ28082861MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasionReducing mucus production after urinary reconstruction: a prospective randomized trialTip60 is a nuclear hormone receptor coactivatorRegulation of FGF8 expression by the androgen receptor in human prostate cancerTip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptorImmunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissueThe potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic targetMultiple newly identified loci associated with prostate cancer susceptibilityPeroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stressEngrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancerGenome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer TypesPALB2, CHEK2 and ATM rare variants and cancer risk: data from COGSThe relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative GroupResponse of Degarelix treatment in human prostate cancer monitored by HR-MAS (1)H NMR spectroscopyGenome-wide association study identifies new prostate cancer susceptibility lociGenetic variation in prostate-specific antigen-detected prostate cancer and the effect of control selection on genetic association studiesIdentification of seven new prostate cancer susceptibility loci through a genome-wide association studySeven prostate cancer susceptibility loci identified by a multi-stage genome-wide association studyIdentification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.Homozygous deletion of gene for glutathione S-transferase M1 in bladder cancer.Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium.Predictors of the use of orthotopic bladder reconstruction after radical cystectomy for bladder cancer: data from a pilot study of 1756 cases 2004-2011.Role of information in preparing men for transrectal ultrasound guided prostate biopsy: a qualitative study embedded in the ProtecT trial.Transurethral prostatic resection or laser therapy for men with acute urinary retention: the ClasP randomized trial.Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial.A prospective randomized trial comparing transurethral resection of the prostate and laser therapy in men with chronic urinary retention: The CLasP study.A randomized trial comparing transurethral resection of the prostate, laser therapy and conservative treatment of men with symptoms associated with benign prostatic enlargement: The CLasP study.Including a 'no active intervention' arm in surgical trials is possible: evidence from the CLasP randomised trial.A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer RiskCirculating Folate and Vitamin B12 and Risk of Prostate Cancer: A Collaborative Analysis of Individual Participant Data from Six Cohorts Including 6875 Cases and 8104 Controls.Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).Missing channels in two-colour microarray experiments: combining single-channel and two-channel data.Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma.
P50
Q21562160-D18D6F45-EBE8-43F9-BF5D-707B1CCD8FAEQ24308715-D0FE4D8F-D09F-4F55-941D-CF8365AFC381Q24319795-9601FA39-AE8C-4592-8501-8A2352E2BCB2Q24648557-F7F7C1F8-7DEB-44EE-ADA6-FB0C6006328DQ24793292-3B4CFF05-B4D7-42B4-A8FD-34FD368C2784Q27649987-108A72BB-6F64-421C-BBC0-D2DD162BDFC2Q28082861-69682413-5CA4-4B79-B540-5D731B8D1C70Q28180881-30474272-B8AD-4B6D-80BF-506947F5F912Q28183184-A56BEDAA-DB91-4DD9-B547-B7D6294E45AAQ28199349-9D9FE4A0-4180-42BE-B59C-7DA4C941703BQ28215985-3B3770EB-2C4C-4EB6-803E-0F40EF2D5BC8Q28216750-F778A65C-40BE-4D73-A263-E2389FCD53B2Q28251349-D690C6B3-0A23-41FB-8450-E4B93641C837Q28259937-1D502E88-2196-4DDD-A059-C49912C75078Q28259937-A7AFFA27-0C8C-487E-9436-819BAD53A2D2Q28268180-6D45CC12-D0B8-4C13-BEC0-F560908FD8DDQ28295105-457AE5B5-A928-4DFC-AFF4-6DAFE86172D4Q28306340-ABEFC286-3B30-4686-B9ED-B02144166F7DQ28388497-1A4B9895-9F02-4523-A557-89ADEFA94BC4Q28584533-9B0F4F8B-42C7-487A-887C-E026504123F5Q28749313-E3E8FB8D-BAB7-4FAB-94F3-7A8E519E3841Q28828349-07AABF10-D4D0-4390-A866-B365394BDF83Q28924380-019EA5C3-16EE-4883-9D90-17075B400326Q28943405-EF89E8B1-DF9B-475D-9A5B-DBAA601B4834Q29417022-8CD89D29-D06F-4D2D-893A-FC58FC4CEA86Q29417074-E206FC97-887B-4F96-B820-CB258E567012Q29417155-48CC203B-910A-4663-AAC2-40A472403A13Q30445553-B05F6FDE-3DEA-4AB8-B9A9-C09DEF2CDE59Q30491647-967D5A1B-8404-4649-9DE7-5216530325BDQ30587187-F54C2749-E058-48DF-BA1E-DC08D9876D3CQ30625083-CA017923-E9EE-4783-91DF-8D8CDF887CA8Q30685579-6FC880B4-A5C0-4839-B217-CC2DD5A594FAQ30703497-4F6A4F1C-85C2-498A-BC6E-17771F214E4BQ30875825-7D5442F2-1661-41C3-BF7E-EEB11D004EC9Q30875838-FC2B3487-0913-4D99-9FBA-221E13E45B95Q31022214-66B55C9B-1EE6-44C0-85A6-9B1D426E7F2AQ31049602-96311037-DCFD-441F-80F5-3AAC4B5867CCQ31072425-B39C140F-5BC4-411B-A70A-DD1551EE05D5Q31088071-293A6624-275C-4273-AB5D-D5C1B91909F5Q31095908-53B32C40-814F-4F26-95BD-CAED301E4106
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
David E. Neal
@ast
David E. Neal
@en
David E. Neal
@es
David E. Neal
@nl
David E. Neal
@sl
type
label
David E. Neal
@ast
David E. Neal
@en
David E. Neal
@es
David E. Neal
@nl
David E. Neal
@sl
altLabel
David E Neal
@en
David Neal
@en
Neal DE
@en
prefLabel
David E. Neal
@ast
David E. Neal
@en
David E. Neal
@es
David E. Neal
@nl
David E. Neal
@sl
P106
P1153
35393852700
P21
P31
P3835
david-neal12
P496
0000-0002-6033-5086